By Robert Kirby, COO, Metrion Biosciences
Last year I worked alongside authors from Amgen and published ‘Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays’ (Nucleic Acid Therapeutics).
I’m delighted this work has received the ‘2024 Technology Innovation Publication Award’ from the Safety Pharmacology Society and send my, and Metrion’s, congratulations to all authors.
Read my earlier post about this work.
Read the full publication: Yusheng Qu, Robert Kirby, Richard Davies, Ayesha Jinat, Stefano Stabilini, Bin Wu, Longchuan Yu, BaoXi Gao, and Hugo M. Vargas, Nucleic Acid Therapeutics 2023 33:2, 132-140.
By Robert Kirby, COO, Metrion Biosciences
Last year I worked alongside authors from Amgen and published ‘Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays’ (Nucleic Acid Therapeutics).
I’m delighted this work has received the ‘2024 Technology Innovation Publication Award’ from the Safety Pharmacology Society and send my, and Metrion’s, congratulations to all authors.
Read my earlier post about this work.
Read the full publication: Yusheng Qu, Robert Kirby, Richard Davies, Ayesha Jinat, Stefano Stabilini, Bin Wu, Longchuan Yu, BaoXi Gao, and Hugo M. Vargas, Nucleic Acid Therapeutics 2023 33:2, 132-140.
By Robert Kirby, COO, Metrion Biosciences
Last year I worked alongside authors from Amgen and published ‘Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays’ (Nucleic Acid Therapeutics).
I’m delighted this work has received the ‘2024 Technology Innovation Publication Award’ from the Safety Pharmacology Society and send my, and Metrion’s, congratulations to all authors.
Read my earlier post about this work.
Read the full publication: Yusheng Qu, Robert Kirby, Richard Davies, Ayesha Jinat, Stefano Stabilini, Bin Wu, Longchuan Yu, BaoXi Gao, and Hugo M. Vargas, Nucleic Acid Therapeutics 2023 33:2, 132-140.